CN113350494A - A Chinese medicinal composition for transdermal administration for treating infectious diseases, and its preparation method - Google Patents
A Chinese medicinal composition for transdermal administration for treating infectious diseases, and its preparation method Download PDFInfo
- Publication number
- CN113350494A CN113350494A CN202110445838.1A CN202110445838A CN113350494A CN 113350494 A CN113350494 A CN 113350494A CN 202110445838 A CN202110445838 A CN 202110445838A CN 113350494 A CN113350494 A CN 113350494A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- vaccine
- infectious diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 208000035473 Communicable disease Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000003814 drug Substances 0.000 claims abstract description 101
- 229960005486 vaccine Drugs 0.000 claims abstract description 52
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims abstract description 41
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 13
- 241000334160 Isatis Species 0.000 claims abstract description 13
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims abstract description 13
- 241001116389 Aloe Species 0.000 claims abstract description 12
- 235000001405 Artemisia annua Nutrition 0.000 claims abstract description 12
- 240000000011 Artemisia annua Species 0.000 claims abstract description 12
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 12
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 12
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 12
- 244000118350 Andrographis paniculata Species 0.000 claims abstract description 11
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 11
- 240000004980 Rheum officinale Species 0.000 claims abstract description 11
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 11
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 11
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 11
- 201000001352 cholecystitis Diseases 0.000 claims abstract description 11
- 206010022000 influenza Diseases 0.000 claims abstract description 11
- 206010003011 Appendicitis Diseases 0.000 claims abstract description 10
- 206010033078 Otitis media Diseases 0.000 claims abstract description 10
- 241000972672 Phellodendron Species 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 206010044008 tonsillitis Diseases 0.000 claims abstract description 10
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 10
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000008297 liquid dosage form Substances 0.000 claims description 3
- 239000008299 semisolid dosage form Substances 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- 239000007909 solid dosage form Substances 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- 244000301850 Cupressus sempervirens Species 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 241000123725 Sophora tonkinensis Species 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 238000013271 transdermal drug delivery Methods 0.000 abstract description 10
- 239000007924 injection Substances 0.000 abstract description 8
- 238000002347 injection Methods 0.000 abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 5
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 14
- 241000245665 Taraxacum Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 241000219784 Sophora Species 0.000 description 6
- 240000006688 Telosma cordata Species 0.000 description 6
- 235000017352 Telosma cordata Nutrition 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 206010008617 Cholecystitis chronic Diseases 0.000 description 2
- 206010009152 Chronic tonsillitis Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000746375 Andrographis Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 241000218202 Coptis Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a vaccine traditional Chinese medicine composition for treating infectious diseases by transdermal administration, wherein the vaccine is bacillus calmette guerin, and the traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 0-20 parts of coptis chinensis, 5-20 parts of rheum officinale, 0-9 parts of aloe, 0-16 parts of dandelion, 8-20 parts of isatis root, 6-20 parts of honeysuckle, 5-20 parts of fructus forsythiae, 0-8 parts of andrographis paniculata, 1-10 parts of radix bupleuri, 2-11 parts of sweet wormwood herb, 0-9 parts of phellodendron and 0-9 parts of scutellaria baicalensis. The invention realizes transdermal drug delivery by means of BCG and traditional Chinese medicine, replaces a painful BCG intradermal injection method, has obvious curative effects on various infectious diseases such as tonsillitis, pneumonia, nasosinusitis, appendicitis, otitis media, cholecystitis, influenza and the like, has short treatment period of 2 to 11 days, is simple to use, does not need injection or medicine taking, has no side effect, takes effect quickly, and replaces antibiotics by traditional Chinese medicine.
Description
Technical Field
The invention relates to the technical field of transdermal administration of pharmaceutical compositions, in particular to a vaccine traditional Chinese medicine composition for treating infectious diseases by transdermal administration and a preparation method thereof.
Background
Transdermal drug delivery is one method of drug absorption through the skin. The process of the drug passing through the stratum corneum after application to the skin, diffusing through the skin, being absorbed by the capillaries or lymphatic vessels into the systemic circulation is called percutaneous absorption or transdermal absorption. Transdermal administration has its unique advantages. Such as: transdermal administration can avoid first pass effect of liver and degradation of medicine in gastrointestinal tract, and the medicine absorption is not affected by gastrointestinal tract factors, so as to reduce individual difference of medicine administration. Reduces toxic and side effects, is convenient to use, and is particularly suitable for patients who are not suitable for oral administration.
BCG vaccine is live vaccine prepared by freeze drying attenuated bovine tubercle bacillus, and is mainly used for preventing tuberculosis, treating infantile asthmatic bronchitis and adjuvant treating tumor. The administration of BCG is usually intradermal injection or intratumoral injection, and transdermal administration is rarely seen. Patent application CN201210063961.8 provides a method of transdermal drug delivery comprising: disinfecting the skin of the subject; pre-treating the skin of a subject with a microneedle array stamp to create micropores that penetrate the stratum corneum layer of the skin; adhering a transdermal drug delivery cartridge loaded with a drug to be delivered and hyaluronidase to the skin of a subject and keeping for a period of time; and removing the transdermal drug delivery cartridge from the skin of the subject; wherein, the transdermal drug delivery patch contains an antibacterial preservative. The specification of this application specifically mentions a method for treating tuberculosis by transdermal administration of BCG. But actually it needs to make micro-holes on the skin with micro-needle array stamp before transdermal administration and realize transdermal administration of bcg vaccine by means of penetration enhancer hyaluronidase. It can be seen that it does not achieve transdermal administration of bcg without damaging the skin surface layer. Patent application CN201811003395.5 provides a bioabsorbable painless transdermal drug delivery microneedle patch, including the base with fix the needle body that contains the bacterin on the base, the base is prepared by the aqueous solution of soluble material A, the needle body is prepared by needle body preparation liquid, and needle body preparation liquid includes the aqueous solution and the bacterin of soluble material B. In the microneedle patch, the vaccine is uniformly dispersed in the needle body part and can be completely released in the skin, the dissolution of the microneedle solves the problems of secondary harm of medical waste of the needle head after subcutaneous injection administration and the like, and the administration dosage is accurate and the speed is controllable. The specification of this application specifically states that transdermal administration of BCG can be achieved. However, transdermal delivery of this solution, which is essentially accomplished by the microneedles passing through the stratum corneum layer of the skin, requires disruption of the top layer of the skin. It can be seen that transdermal administration of bcg is currently achieved by disrupting the stratum corneum with microneedles and by the penetration-promoting action of hyaluronidase.
In the aspect of treating infectious diseases such as appendicitis, tonsillitis, otitis media, pneumonia, nasosinusitis, cholecystitis, influenza and the like, human beings still adopt injection and oral antibiotics to resist infection or adopt oral traditional Chinese medicines to treat. The search does not find a precedent that the BCG vaccine is combined with the traditional Chinese medicine to treat infectious diseases such as pneumonia and the like by adopting a transdermal administration mode. Therefore, the vaccine traditional Chinese medicine composition for treating infectious diseases by transdermal administration and the preparation method thereof are pioneering achievements in the field, and the traditional Chinese medicine composition has important significance for replacing antibiotics.
Disclosure of Invention
In view of the defects of the prior art, the applicant develops a vaccine traditional Chinese medicine composition for treating infectious diseases by transdermal administration through years of research and summary, and specifically discloses a preparation method and a use method of the vaccine traditional Chinese medicine composition.
The scheme of the invention comprises the following contents:
a vaccine traditional Chinese medicine composition for treating infectious diseases through transdermal administration is a BCG vaccine, and comprises the following traditional Chinese medicine raw materials in parts by weight: 0-20 parts of coptis chinensis, 5-20 parts of rheum officinale, 0-9 parts of aloe, 0-16 parts of dandelion, 8-20 parts of isatis root, 6-20 parts of honeysuckle, 5-20 parts of fructus forsythiae, 0-8 parts of andrographis paniculata, 1-10 parts of radix bupleuri, 2-11 parts of sweet wormwood herb, 0-9 parts of phellodendron and 0-9 parts of scutellaria baicalensis.
Preferably, the traditional Chinese medicine composition also comprises the following traditional Chinese medicine raw materials in parts by weight: 3-10 parts of folium isatidis, 0-10 parts of herba violae, 0-8 parts of rhizoma paridis, 0-3 parts of radix sophorae tonkinensis and 0-8 parts of salvia miltiorrhiza.
Preferably, the traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 10-20 parts of coptis chinensis, 5-20 parts of rheum officinale, 2-9 parts of aloe, 5-16 parts of dandelion, 8-16 parts of isatis root, 6-10 parts of honeysuckle, 5-12 parts of fructus forsythiae, 3-8 parts of andrographis paniculata, 1-3 parts of radix bupleuri, 2-11 parts of sweet wormwood herb, 3-9 parts of golden cypress, 2-9 parts of scutellaria baicalensis, 3-7 parts of folium isatidis, 5-10 parts of herba violae, 3-8 parts of rhizoma paridis, 1-3 parts of vietnamese sophora root and 3-8 parts of salvia miltiorrhiza.
Preferably, the bcg vaccine of the present invention is a whole vaccine.
Preferably, the preparation method of the vaccine traditional Chinese medicine composition comprises the following steps: mixing the Chinese medicinal materials, pulverizing to obtain mixed powder, extracting with organic solvent, and filtering to obtain Chinese medicinal extractive solution which can be used together with BCG vaccine. The dosage ratio of the BCG vaccine to the traditional Chinese medicine raw materials is 0.5-1 mg: 2-12 g.
Preferably, the preparation method of the vaccine traditional Chinese medicine composition comprises the following steps: mixing and crushing traditional Chinese medicine raw materials to obtain mixed medicinal powder, wherein the ratio of materials to liquid is 20-60 g: leaching 100mL of the extract with an ethanol solution with the volume concentration of 60-80% for 1-2 weeks, and filtering to obtain a traditional Chinese medicine extract, wherein the traditional Chinese medicine extract and the BCG are used simultaneously.
The invention relates to a traditional Chinese medicine vaccine preparation for treating infectious diseases by transdermal administration, which takes the traditional Chinese medicine vaccine composition as an effective component. Preferably, the vaccine traditional Chinese medicine preparation further comprises pharmaceutically acceptable auxiliary materials, and the dosage of the auxiliary materials is added according to the pharmaceutical requirements.
The pharmaceutically acceptable adjuvants include ethanol, menthol, azone and sodium chloride.
Preferably, the dosage form of the vaccine traditional Chinese medicine preparation is a transdermal administration dosage form, and the dosage form comprises a liquid dosage form, a semisolid dosage form, a solid dosage form or a gas dosage form.
Preferably, the liquid dosage form comprises lotion and liniment, the semisolid dosage form comprises ointment, gel and paste, the solid dosage form comprises emplastrum and powder, and the gas dosage form comprises aerosol.
Preferably, the infectious diseases comprise appendicitis, tonsillitis, otitis media, pneumonia, nasosinusitis, cholecystitis and influenza.
The invention provides two using modes of a BCG vaccine traditional Chinese medicine composition: 1) firstly, 1-5 mL of auxiliary materials such as azone and the like are smeared on the shank and/or the thigh to be dried, and then 1-2 mL of BCG vaccine and 10-20 mL of traditional Chinese medicine extracting solution are smeared; 1-3 times a day; 2) firstly, preparing the BCG vaccine and the traditional Chinese medicine extracting solution into a BCG vaccine traditional Chinese medicine mixed preparation, smearing auxiliary materials (1-5 mL) such as azone on legs and/or thighs for drying before use, and then smearing the preparation. 1-3 times a day.
The compatibility relationship of the components in the vaccine traditional Chinese medicine composition is as follows:
in the formula, coptis, phellodendron, scutellaria, common andrographis, honeysuckle, forsythia, dandelion and isatis root are used as monarch drugs for clearing heat and purging fire, clearing heat and removing toxicity and resisting inflammation; aloe, radix et rhizoma Rhei, herba Artemisiae Annuae, bupleuri radix purgative, relieving exterior syndrome, cooling blood, and removing heat as ministerial drugs. Folium Isatidis, herba Violae, rhizoma paridis, radix Sophorae Tonkinensis and Saviae Miltiorrhizae radix are used as adjuvant drugs. The medicines are used together to achieve the effect of treating infectious diseases by transdermal administration.
The invention has the following beneficial effects:
A. the invention combines 0.5mg/1ml of BCG originally used for intradermal injection with traditional Chinese medicines, realizes transdermal drug delivery by the BCG and the traditional Chinese medicines, and replaces a painful BCG intradermal injection method.
B. The BCG vaccine and traditional Chinese medicine composition formula has obvious curative effects on various infectious diseases such as tonsillitis, pneumonia, nasosinusitis, appendicitis, otitis media, cholecystitis, influenza and the like, and has short treatment period and quick response.
C. The traditional Chinese medicine composition disclosed by the invention is combined with the BCG vaccine whole vaccine for use, the skin surface layer is not required to be damaged, the traditional Chinese medicine composition and the BCG vaccine mutually promote penetration, the transdermal absorption rate of the drug effect components is accelerated, the dosage is reduced, and the treatment period is shortened.
Detailed Description
In order to better understand the technical content of the invention, specific examples are provided below to further illustrate the invention.
Example 1
A vaccine traditional Chinese medicine composition for treating infectious diseases by percutaneous administration comprises a BCG vaccine whole vaccine (specification is 0.5mg/1mL) and the following traditional Chinese medicine raw materials in parts by weight: 10 parts of coptis chinensis, 3 parts of phellodendron, 5 parts of scutellaria baicalensis, 20 parts of rheum officinale, 2 parts of aloe, 5 parts of dandelion, 10 parts of isatis root, 6 parts of honeysuckle, 10 parts of fructus forsythiae, 5 parts of folium isatidis, 5 parts of Chinese violet, 5 parts of andrographis paniculata, 1 part of radix bupleuri, 3 parts of rhizoma paridis, 3 parts of subprostrate sophora, 4 parts of sweet wormwood and 3 parts of salvia miltiorrhiza.
Example 2
A vaccine traditional Chinese medicine composition for treating infectious diseases by percutaneous administration comprises a BCG vaccine whole vaccine (specification is 0.5mg/1mL) and the following traditional Chinese medicine raw materials in parts by weight: 12 parts of coptis chinensis, 5 parts of phellodendron, 5 parts of scutellaria baicalensis, 13 parts of rheum officinale, 2 parts of aloe, 5 parts of dandelion, 8 parts of isatis root, 7 parts of honeysuckle, 7 parts of fructus forsythiae, 3 parts of folium isatidis, 5 parts of Chinese violet, 8 parts of andrographis paniculata, 3 parts of radix bupleuri, 8 parts of rhizoma paridis, 3 parts of subprostrate sophora, 2 parts of sweet wormwood and 4 parts of salvia miltiorrhiza.
Example 3
A vaccine traditional Chinese medicine composition for treating infectious diseases by percutaneous administration comprises a BCG vaccine whole vaccine (specification is 0.5mg/1mL) and the following traditional Chinese medicine raw materials in parts by weight: 12 parts of coptis chinensis, 9 parts of phellodendron, 3 parts of scutellaria baicalensis, 13 parts of rheum officinale, 3 parts of aloe, 6 parts of dandelion, 8 parts of isatis root, 6 parts of honeysuckle, 12 parts of fructus forsythiae, 3 parts of folium isatidis, 6 parts of Chinese violet, 3 parts of andrographis paniculata, 2 parts of radix bupleuri, 3 parts of rhizoma paridis, 1 part of subprostrate sophora, 2 parts of sweet wormwood and 8 parts of salvia miltiorrhiza.
Example 4
A vaccine traditional Chinese medicine composition for treating infectious diseases by percutaneous administration comprises a BCG vaccine whole vaccine (specification is 0.5mg/1mL) and the following traditional Chinese medicine raw materials in parts by weight: 20 parts of coptis chinensis, 3 parts of phellodendron, 2 parts of scutellaria baicalensis, 13 parts of rheum officinale, 2 parts of aloe, 14 parts of dandelion, 8 parts of isatis root, 6 parts of honeysuckle, 5 parts of fructus forsythiae, 4 parts of folium isatidis, 10 parts of Chinese violet, 3 parts of andrographis paniculata, 1 part of radix bupleuri, 3 parts of rhizoma paridis, 1 part of subprostrate sophora, 2 parts of sweet wormwood and 3 parts of salvia miltiorrhiza.
Example 5
A vaccine traditional Chinese medicine composition for treating infectious diseases by percutaneous administration comprises a BCG vaccine whole vaccine (specification is 0.5mg/1mL) and the following traditional Chinese medicine raw materials in parts by weight: 10 parts of coptis chinensis, 3 parts of phellodendron, 2 parts of scutellaria baicalensis, 14 parts of rheum officinale, 2 parts of aloe, 16 parts of dandelion, 16 parts of isatis root, 10 parts of honeysuckle, 5 parts of fructus forsythiae, 3 parts of folium isatidis, 5 parts of Chinese violet, 3 parts of andrographis paniculata, 1 part of radix bupleuri, 3 parts of rhizoma paridis, 1 part of subprostrate sophora, 3 parts of sweet wormwood and 3 parts of salvia miltiorrhiza.
Example 6
A vaccine traditional Chinese medicine composition for treating infectious diseases by percutaneous administration comprises a BCG vaccine whole vaccine (specification is 0.5mg/1mL) and the following traditional Chinese medicine raw materials in parts by weight: 12 parts of coptis chinensis, 5 parts of phellodendron, 9 parts of scutellaria baicalensis, 5 parts of rheum officinale, 9 parts of aloe, 5 parts of dandelion, 8 parts of isatis root, 6 parts of honeysuckle, 6 parts of fructus forsythiae, 7 parts of folium isatidis, 5 parts of Chinese violet, 3 parts of andrographis paniculata, 3 parts of radix bupleuri, 8 parts of rhizoma paridis, 3 parts of subprostrate sophora, 3 parts of sweet wormwood and 3 parts of salvia miltiorrhiza.
Example 7
A vaccine traditional Chinese medicine composition for treating infectious diseases by percutaneous administration comprises a BCG vaccine whole vaccine (specification is 0.5mg/1mL) and the following traditional Chinese medicine raw materials in parts by weight: 20 parts of isatis root, 10 parts of dyers woad leaf, 20 parts of weeping forsythia, 20 parts of honeysuckle flower, 10 parts of bupleurum root, 9 parts of rhubarb and 11 parts of sweet wormwood herb.
The vaccines used in examples 1-7 were whole BCG vaccines. The traditional Chinese medicine raw materials are extracted by ethanol to obtain traditional Chinese medicine extracting solution for use. The traditional Chinese medicine extracting solution is as follows: taking all the traditional Chinese medicine raw materials, crushing, mixing, and mixing according to a material-liquid ratio of 50 g: 100mL of the extract was extracted with 75% by volume of an ethanol solution for 1 week, and the resulting ethanol extract was filtered.
The application mode of the vaccine traditional Chinese medicine composition in the embodiment 1-7 is as follows: firstly, coating azone (about 5mL) on legs and thighs to be dried, and then coating 1-2 mL of BCG vaccine (intradermal injection, specification of 0.5mg/1mL) and 10-20 mL of traditional Chinese medicine extracting solution; the dosage is 2 times a day.
In addition, the ratio of the materials to the liquid can be 20-60 g: 100mL, and leaching for 1-2 weeks. The concentration of the traditional Chinese medicine ethanol extract is properly adjusted, so that the effect of the medicine is not obviously influenced.
In order to be used conveniently, the vaccine traditional Chinese medicine composition can be added with auxiliary materials to be prepared into other transdermal administration dosage forms such as ointment and the like.
The treatment effect of the scheme of the invention is fully verified in the practical application process. The treatment results for years show that the vaccine traditional Chinese medicine composition or preparation provided by the invention has obvious curative effects on various infectious diseases such as appendicitis, tonsillitis, otitis media, pneumonia, nasosinusitis, cholecystitis, influenza and the like. The inventor commonly uses the scheme of the invention for more than 50 cases of chronic tonsillitis for years, treats more than 20 cases of appendicitis, otitis media, pneumonia, nasosinusitis, cholecystitis and influenza, and has the cure rate of more than 95 percent after statistics. The following table 1 provides diagnostic criteria and therapeutic efficacy judgment criteria for treating the above diseases. Cases diagnosed by hospitals above the county level can be redetermined without following the table below.
TABLE 1
According to statistics, the treatment course of curing appendicitis, tonsillitis, otitis media, pneumonia and cholecystitis in the scheme is 5-6 days, the treatment course of curing pneumonia is 7-8 days, the treatment course of nasosinusitis is 9-11 days, and the treatment course of influenza is 2-4 days. The formulas of the above examples 1 to 7 are respectively the optimal formulas for treating appendicitis, tonsillitis, otitis media, pneumonia, sinusitis, cholecystitis and influenza in sequence.
Some treatment cases are provided below, and the prescription used in each case is the formula provided in the above examples 1 to 7 (the formula of examples 1 to 7 is used in sequence in case 1 to case 7).
Case 1: the medicine is suitable for men, is 66 years old, has chronic tonsillitis, suppuration and fever in the young, has the bouts once every 3 to 5 days, and has no effect after the treatment by using various antibiotics and traditional Chinese medicines, the tonsil is removed by an operation, but the operation is still poor, and the life, the study and the work are influenced. After the BCG vaccine and the traditional Chinese medicine are administrated for 5 days in 83 years and 7 months, the disease is cured, and no relapse occurs.
Case 2: aged XX, female, aged 67 years, with pneumonia (8 months in 2003 and 3 months in 2014) twice to county level medical department, taking X-ray film to confirm diagnosis, fever 39-40 degrees, severe cough, poor appetite, bedridden, and recovery after 7 days of BCG (bacillus calmette guerin) and traditional Chinese medicine transdermal drug delivery treatment without antibiotic treatment. After 4 years of follow-up, the body is completely recovered, and cold is rarely caused.
Case 3: forest XX, women, 51 years old, chief complaint several years ago have sinusitis, headache, nasal obstruction, running nasal discharge, visit and use many antibiotics treatment effect not good in county level hospital, give calmette-guerin vaccine + traditional chinese medicine percutaneous administration treatment 9 days of clinical symptoms disappear in 2006, beat CT piece more than 1-2 months, suggest that each sinus intracavity shows well, follow-up visit two years after fully recovering has no recurrence.
Case 4: xue XX, male, 53 years old, acute appendicitis in 9 months 2003, the B-ultrasound diagnosis in county level hospital, pain difficult to endure, vomit after eating, at that time, BCG + Chinese traditional medicine percutaneous medication treatment is given for 5 days, then recovery is achieved, and no recurrence is seen until now in 3 years.
Case 5: the king XX is a medicine for women, the women are 11 years old, the patients with otitis media, pain is difficult to endure, two ears are purulent, hearing is declined before 5 years old, after 5 days of treatment by bcg vaccine and traditional Chinese medicine transdermal administration, symptoms such as ear pain, ear purulence, hearing decline and the like disappear, and no recurrence is found in 6 years follow-up.
Case 6: the symbol XX shows that the female is 50 years old, suffers from chronic cholecystitis 11 years ago, feels dull pain under the right rib, is full of fullness and aggravates when eating greasy food, looks like knife cutting when aggravating, and is diagnosed as the chronic cholecystitis by hospitals. The effect is not good after the antibiotics treatment is frequently used, after the BCG vaccine and the traditional Chinese medicine are used for percutaneous administration treatment for 5 days, the symptoms disappear, the gallbladder is checked to be normal by B ultrasonic, no relapse occurs in 7 years of follow-up visit, and the mental state is good.
Case 7: yellow XX, male, 10 years old, 6 years old, flu season had flu (county level diagnosis) cold, fever 39-40 degrees, cough, runny nose, headache intolerable, given BCG vaccine and traditional Chinese medicine transdermal drug delivery treatment after 3 days to recover.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. The vaccine traditional Chinese medicine composition for treating infectious diseases through transdermal administration is characterized in that the vaccine is bacillus calmette guerin, and the traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 0-20 parts of coptis chinensis, 5-20 parts of rheum officinale, 0-9 parts of aloe, 0-16 parts of dandelion, 8-20 parts of isatis root, 6-20 parts of honeysuckle, 5-20 parts of fructus forsythiae, 0-8 parts of andrographis paniculata, 1-10 parts of radix bupleuri, 2-11 parts of sweet wormwood herb, 0-9 parts of phellodendron and 0-9 parts of scutellaria baicalensis.
2. The vaccine traditional Chinese medicine composition for treating infectious diseases through transdermal administration according to claim 1, which is characterized by further comprising the following traditional Chinese medicine raw materials in parts by weight: 3-10 parts of folium isatidis, 0-10 parts of herba violae, 0-8 parts of rhizoma paridis, 0-3 parts of radix sophorae tonkinensis and 0-8 parts of salvia miltiorrhiza.
3. The vaccine traditional Chinese medicine composition for treating infectious diseases through transdermal administration according to claim 1, which is characterized by comprising the following traditional Chinese medicine raw materials in parts by weight: 10-20 parts of coptis chinensis, 5-20 parts of rheum officinale, 2-9 parts of aloe, 5-16 parts of dandelion, 8-16 parts of isatis root, 6-10 parts of honeysuckle, 5-12 parts of fructus forsythiae, 3-8 parts of andrographis paniculata, 1-3 parts of radix bupleuri, 2-11 parts of sweet wormwood herb, 3-9 parts of golden cypress, 2-9 parts of scutellaria baicalensis, 3-7 parts of folium isatidis, 5-10 parts of herba violae, 3-8 parts of rhizoma paridis, 1-3 parts of vietnamese sophora root and 3-8 parts of salvia miltiorrhiza.
4. The method for preparing the vaccine traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine raw materials are mixed and then crushed to obtain mixed medicinal powder, the mixed medicinal powder is extracted by an organic solvent and filtered to obtain traditional Chinese medicine extracting solution, and the traditional Chinese medicine extracting solution and the BCG vaccine are used simultaneously; the dosage ratio of the BCG vaccine to the traditional Chinese medicine raw materials is 0.5-1 mg: 2-12 g.
5. The method of claim 4, comprising the steps of: mixing and crushing traditional Chinese medicine raw materials to obtain mixed medicinal powder, wherein the ratio of materials to liquid is 20-60 g: leaching 100mL of the extract with an ethanol solution with the volume concentration of 60-80% for 1-2 weeks, and filtering to obtain a traditional Chinese medicine extract, wherein the traditional Chinese medicine extract and the BCG are used simultaneously.
6. A traditional Chinese medicine vaccine preparation for treating infectious diseases by transdermal administration, which is characterized in that the traditional Chinese medicine vaccine preparation takes the traditional Chinese medicine vaccine composition of claim 1 as an effective component.
7. The Chinese medicinal preparation of claim 6, wherein the vaccine Chinese medicinal preparation further comprises pharmaceutically acceptable adjuvants, and the adjuvants are added according to pharmaceutical requirements.
8. The vaccine traditional Chinese medicine preparation according to claim 7, wherein the pharmaceutically acceptable adjuvants comprise ethanol, menthol, azone and sodium chloride.
9. The vaccine traditional Chinese medicine preparation according to claim 6, wherein the dosage form of the vaccine traditional Chinese medicine preparation is a transdermal administration dosage form, and the dosage form comprises a liquid dosage form, a semisolid dosage form, a solid dosage form or a gas dosage form.
10. The vaccine composition of claim 1 or the vaccine preparation of claim 7, wherein the infectious diseases include appendicitis, tonsillitis, otitis media, pneumonia, sinusitis, cholecystitis, and influenza.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110445838.1A CN113350494A (en) | 2021-04-25 | 2021-04-25 | A Chinese medicinal composition for transdermal administration for treating infectious diseases, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110445838.1A CN113350494A (en) | 2021-04-25 | 2021-04-25 | A Chinese medicinal composition for transdermal administration for treating infectious diseases, and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113350494A true CN113350494A (en) | 2021-09-07 |
Family
ID=77525408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110445838.1A Pending CN113350494A (en) | 2021-04-25 | 2021-04-25 | A Chinese medicinal composition for transdermal administration for treating infectious diseases, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113350494A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911412A (en) * | 2006-08-17 | 2007-02-14 | 郑庆华 | External application traditional Chinese medicine for teating acne |
| CN101411804A (en) * | 2007-10-19 | 2009-04-22 | 鞍山钢铁集团公司 | Mixture for clearing lung-heat and preparation method thereof |
| CN104547680A (en) * | 2014-12-25 | 2015-04-29 | 北京亚东生物制药有限公司 | Liniment used for fever in children and acute tonsillitis in children |
| CN110302284A (en) * | 2019-08-14 | 2019-10-08 | 张嗣喜 | Treat anginal Chinese medicine composition |
| CN112603955A (en) * | 2021-01-14 | 2021-04-06 | 北京万辉双鹤药业有限责任公司 | Preparation and preparation method of children anti-inflammatory drug |
-
2021
- 2021-04-25 CN CN202110445838.1A patent/CN113350494A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911412A (en) * | 2006-08-17 | 2007-02-14 | 郑庆华 | External application traditional Chinese medicine for teating acne |
| CN101411804A (en) * | 2007-10-19 | 2009-04-22 | 鞍山钢铁集团公司 | Mixture for clearing lung-heat and preparation method thereof |
| CN104547680A (en) * | 2014-12-25 | 2015-04-29 | 北京亚东生物制药有限公司 | Liniment used for fever in children and acute tonsillitis in children |
| CN110302284A (en) * | 2019-08-14 | 2019-10-08 | 张嗣喜 | Treat anginal Chinese medicine composition |
| CN112603955A (en) * | 2021-01-14 | 2021-04-06 | 北京万辉双鹤药业有限责任公司 | Preparation and preparation method of children anti-inflammatory drug |
Non-Patent Citations (3)
| Title |
|---|
| 李冠棠: "消炎十三味方的临床运用", 《江西中医药》 * |
| 祝文兵，等: "银花抗病毒合剂的制备与质量控制", 《中国医院用药评价与分析》 * |
| 陈会甫，等: "外用退热药酒治疗各种原因引起的高热100例", 《中医外治杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101524524B (en) | Drug for treating severe cold and preparation method thereof | |
| CN105833279B (en) | External-use medicine composition for treating various wound surfaces of skin and preparation method thereof | |
| CN109394959A (en) | It is a kind of to have effects that repair the Chinese medicine composition of keratoderma and its water extract and fermentation material and application | |
| CN103356824B (en) | Traditional Chinese medicine based narcotic drug used for tooth extraction operation and preparation method thereof | |
| CN104800700B (en) | It is a kind of to treat dermopathic herbal composite | |
| CN105663928A (en) | Ointment for treating skin diseases of animals as well as preparation method of ointment | |
| CN114767824B (en) | Preparation for treating laryngeal cough and preparation method thereof | |
| CN113350494A (en) | A Chinese medicinal composition for transdermal administration for treating infectious diseases, and its preparation method | |
| CN105079420A (en) | Anesthesia ointment for wound surface and preparation method of anesthesia ointment | |
| CN1931208B (en) | Application of common goldenrod herb in preparing medicine for preventing and treating H5N1 bird flu and influenza | |
| CN110384785B (en) | A topical Chinese medicinal liquid for treating viral common cold, and its preparation method | |
| CN113318158A (en) | A topical composition for treating rhinitis and preparation method thereof | |
| CN103239594B (en) | Topical pharmaceutical composition for preventing and treating canine acariasis disease and preparation method thereof | |
| CN104857392A (en) | Vaginal suppository for treating mycotic vaginitis as well as preparation and use methods of vaginal suppository | |
| CN104922620A (en) | Application of Sang Jiang Cold Injection (mulberry leaf and ginger cold injection) to preparation of aerosolization and rectal administration preparation and preparation method of Sang Jiang Cold Injection | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| CN1157736A (en) | Special medications ticking sheet dispensing for pneumonia therapeutic equipment and production technology | |
| CN108420980A (en) | It is a kind of treat skin injury, bacterium infection antibacterial ointment and preparation method thereof | |
| CN115463182B (en) | Traditional Chinese medicine composition and gel preparation and application thereof in preventing and treating radiodermatitis | |
| CN103028049B (en) | Traditional Chinese medicine composition for treating tinea manuum and preparation method of composition | |
| CN112755101B (en) | Traditional Chinese medicine composition for treating knee osteoarthritis and application thereof | |
| CN116211926B (en) | Application of Jingfeng preparation in preparing anti-helicobacter pylori medicine | |
| CN108403799B (en) | Traditional Chinese medicine composition, gel, preparation method and application thereof | |
| CN108465006B (en) | Composition and plaster for treating knee osteoarthritis | |
| CN109091535B (en) | Pharmaceutical composition for treating mosquito bite dermatitis and preparation process and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210907 |
|
| RJ01 | Rejection of invention patent application after publication |